伦敦, 英国- 11月4日, 2021 – im体育APP Materials 技术 (im体育APP) has signed an agreement to acquire JMI Laboratories (JMI) based in North Liberty, 爱荷华州. Alongside several other significant acquisitions within the sector this year, this further strengthens im体育APP’s offering for pharmaceutical 和 biopharmaceutical customers in North America 和 beyond.
JMI is a market leader in antimicrobial resistance monitoring studies utilized for US-FDA regulatory 和 new drug application submissions, through their proprietary SENTRY 抗菌 Surveillance Program. It offers microbiology 和 molecular testing services to assist in the development of new antimicrobials 和 clinical trial support. The Company is CLIA accredited 和 able to test under GLP conditions.
The business is notable for its team of highly scientific 和 well-published industry recognized experts in the field, including 10 MD/PhDs with extensive knowledge of microbiology 和 antimicrobials, 和 can consult on a broad range of scientific topics covering epidemiology, mechanisms of resistance in bacterial 和 fungal organisms, microbiology diagnostics 和 susceptibility testing methods.
乔Wetz, im体育APP 首席执行官, said: “im体育APP’s growing life sciences capability is now our most significant end market, 和 the acquisition of JMI further confirms our commitment 和 intention to continue to build a scale business in this vital sector. It follows on from our recently announced acquisitions which include ALG, Avomeen, 拱科学, Impact Analytical 和 Nanosyn, complementing our existing expertise 和 exp和ing our customer offering”.
“The acquisition significantly extends our life sciences capability 和 the ability to offer customers services right through from early stage drug development to post FDA approval surveillance programs.”
“JMI’s SENTRY surveillance program, with over 20 years of data from over 130 hospitals across 40 countries, is a real differentiator. Resistance to antibiotics is a clear 和 present threat to public health on a global scale. With JMI’s team of renowned experts, im体育APP is now positioned to play an important role in helping to address the growing risk of antimicrobial resistance.”
JMI首席执行官, Andrew Fuhrmeister commented: “After 20 years of operation 和 having built a strong reputation for our expertise 和 client relationships, we are proud to be joining the im体育APP group. This move will bring us wider global access through the im体育APP network 和 will allow us to work within the exp和ed life sciences offering, building industry leadership.”
The JMI SENTRY surveillance program currently operates with over 130 hospitals around the globe, collecting clinical bacterial 和 fungal isolates from numerous infection sites including bloodstream, 皮肤, 呼吸, patients hospitalized with pneumonia, 尿路, 腹腔, 和 invasive fungal infections. The company collects 和 tests over 40K isolates a year from over 40 nations to provide its pharmaceutical 和 biotech customers with data that is a strong representation of potential resistance issues in most regions across the globe. The acquisition of JMI is subject to approval from CFIUS.
关于im体育APP
The im体育APP Materials 技术 Group is one of the world’s leading global providers of testing, inspection 和 certification services for a diverse range of products, materials 和 technologies in advanced industrial supply chains where failure in use is not an option. 总部设在伦敦, UK, im体育APPc 7,000名科学家, engineers 和 technologists, working in our global network of over 200 laboratories, support customers from early R&D, through complex regulatory approvals 和 into production ensuring their products are safe, sustainable 和 achieve market access.
In 2021, im体育APP设定了它的新, industry leading environmental commitments, adopting science-based targets 和 committing to net zero emissions across its entire global business by 2035. These environmental commitments follow im体育APP’s achievement of the highest ESG ranking in the testing, inspection 和 certification industry from Sustainalytics, a global leader in ESG research 和 data.
For more information about im体育APP, please visit our 网站请与我们联系 LinkedIn 和 推特 并订阅我们的 Youtube 通道.
BroadOak Capital Partners served as JMI’s exclusive financial adviser on the transaction.
媒体联系人:
Devan LaBrash, Pagoda Public Relations
T: +44 (0) 131 556 0770
“The acquisition significantly extends our life sciences capability 和 the ability to offer customers services right through from early stage drug development to post FDA approval surveillance programs.”
乔Wetz
首席执行官